• Title/Summary/Keyword: Molecular imaging

Search Result 817, Processing Time 0.029 seconds

Fluorescence Molecular Imaging

  • Choi, Heung-Kook;Ntziachristos, Vasilis;Weissleder, Ralph
    • Proceedings of the KSMRM Conference
    • /
    • 2004.09a
    • /
    • pp.23-32
    • /
    • 2004
  • The chemotherapy sensitive Lewis lung carcinoma (LLC) and chemotherapy resistant Lewis lung carcinoma (CR-LLC) tumors concurrently implanted in mice, and compare these findings with histological macroscopic observations against 3D reconstruction of Fluorescence Molecular Tomography (FMT) preformed in vivo on the same animals. For the 3D image reconstruction we used 32 laser source images, a flat image and 3D surface rendering that confused for 3D Fluorescence Molecular Imaging (FMI). A minimum of ten tissue sections were analyzed per tumor for quantification of the TUNEL-positive cells, cell-associated Cy5.5-Annexin and vessel-associated Alexa Fluor-Lectin. These are useful apoptosis and angiogenesis markers, and they serve as validation experiments to data obtained in vivousing a Cy5.5-Annexin V conjugate injected intravenously in chemotherapy-treated animals carrying the tumors studied histologically. We detected higher levels of apoptosis and corresponding higher levels of Cy5.5 fluorescence in the LLC vs. the CR-LLC tumors according to tissue depth and these findings confirm that in vivo staining with the Cy5.5-Annexing conjugate correlates well with in vitro TUNEL staining and is consistent with the higher apoptotic index expected from the LLC line. There appeared to be 1.38% more apoptosis for LLC than CR-LLC. Consequently there is good correlation between the histology results and in vivo fluorescence-mediated optical imaging. In conclusion the apoptotic images of 3D FMI were validated by microscopic histological image analysis. This is a significant result for the continuous progress of fluorescence 3D imaging research.

  • PDF

Isolated Splenic Metastasis of Sigmoid Colon Cancer Detected by $^{18}F-FDG$ PET/CT ($^{18}F-FDG$ PET/CT 에서 발견된 S상 결장암의 단일 비장 전이)

  • An, Young-Sil;Yoon, Joon-Kee;Hong, Seon-Pyo;Choi, Bong-Hoi;Joh, Chul-Woo;Yoon, Seok-Nam
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.41 no.3
    • /
    • pp.263-264
    • /
    • 2007
  • Splenic metastasis from colon carcinoma are rare and usually occur in the presence of disseminated visceral metastasis. The liver is the most common site of metastatic spread from colon cancer. Several hypotheses have attempted to explain the low incidence of splenic metastasis. It should be difficult for colorectal cancer cells to reach the spleen through the portal venous system, in which the blood flow is usually from the spleen to the liver. Reticuloendothelial system or rhythmic contraction of the spleen may squeeze out the tumor in the spleen. The absence of afferent lymphatic to the spleen, phagocytic activity and humoral anticancer substances are considered to be other reason for low incidence of splenic metastasis. We report the case of $^{18}F-FDG$ PET/CT finding in a 70-year-old woman who develop isolated splenic metastasis of sigmoid colon cancer.

Development of Optical Molecular Imaging System for the Acquisition of Bioluminescence Signals from Small Animals (소동물 발광영상 측정을 위한 광학분자영상기기의 개발)

  • Lee, Byeong-Il;Kim, Hyeon-Sik;Jeong, Hye-Jin;Lee, Hyung-Jae;Moon, Seung-Min;Kwon, Seung-Young;Choi, Eun-Seo;Jeong, Shin-Young;Bom, Hee-Seung;Min, Jung-Joon
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.43 no.4
    • /
    • pp.344-351
    • /
    • 2009
  • Purpose: Optical imaging is providing great advance and improvement in genetic and molecular imaging of animals and humans. Optical imaging system consists of optical imaging devices, which carry out major function for monitoring, tracing, and imaging in most of molecular in-vivo researches. In bio-luminescent imaging, small animals containing luciferase gene locally irradiate light, and emitted photons transmitted through skin of the small animals are imaged by using a high sensitive charged coupled device (CCD) camera. In this paper, we introduced optical imaging system for the image acquisition of bio-luminescent signals emitted from small animals. Materials and Methods: In the system, Nikon lens and four LED light sources were mounted at the inside of a dark box. A cooled CCD camera equipped with a control module was used. Results: We tested the performance of the optical imaging system using effendorf tube and light emitting bacteria which injected intravenously into CT26 tumor bearing nude mouse. The performance of implemented optical imaging system for bio-luminescence imaging was demonstrated and the feasibility of the system in small animal imaging application was proved. Conclusion: We anticipate this system could be a useful tool for the molecular imaging of small animals adaptable for various experimental conditions in future.

Medical Imaging and Nuclear Molecular Imaging Probes for Pulmonary Fibrosis Diagnosis

  • Heesu Ahn;Yong Jin Lee
    • Journal of Radiopharmaceuticals and Molecular Probes
    • /
    • v.8 no.2
    • /
    • pp.103-111
    • /
    • 2022
  • Idiopathic pulmonary fibrosis (IPF) is a progressive disease caused by some risk factors, including smoking, viral infection, toxic substances, and radiation, that decline lung function of fresh oxygen and blood delivery throughout the body. Patients with pulmonary fibrosis have suffered from breathing and cough and the average survival rate is only 3 years after diagnosis. Therefore, it is significant to diagnose IPF and start treatment in enough time. Usually, lung biopsy is available to diagnose localized pulmonary fibrotic sites directly. However, it is insufficient to visualize whole lung tissue, and also it has a risk of infection for patients. In the clinic, medical imaging systems can diagnose pulmonary fibrosis non-invasively without infection. In this review, we introduce current medical imaging systems used to diagnose pulmonary fibrosis, including CT, MRI, and nuclear medicine. Further, we introduce several molecular imaging probes targeting specific biomarkers which are expressed in pulmonary fibrosis. Through this paper, it is expected that it would be helpful to understand the latest knowledge and research trends on pulmonary fibrosis diagnostic imaging.

Optimized TOF-PET detector using scintillation crystal array for brain imaging

  • Leem, Hyuntae;Choi, Yong;Jung, Jiwoong;Park, Kuntai;Kim, Yeonkyeong;Jung, Jin Ho
    • Nuclear Engineering and Technology
    • /
    • v.54 no.7
    • /
    • pp.2592-2598
    • /
    • 2022
  • Research groups in the field of PET instrumentation are studying time-of-flight(TOF) technology to improve the signal-to-noise ratio of PET images. Scintillation light transport and collection plays an important role in improving the coincidence resolving time(CRT) of PET detector based on a pixelated crystal array. Four crystal arrays were designed by the different optical reflection configuration such as external reflectors and surface treatment on the CRT and compared with the light output, energy resolution and CRT. The design proposed in the study was composed of 8 × 8 LYSO crystal array consisted of 3 × 3 × 15 mm3 pixels. The entrance side was roughened while the other five surfaces were polished. Four sides of all crystal pixels were wrapped with ESR-film, and the entrance surface was covered by Teflon-tape. The design provided an excellent timing resolution of 210 ps and improved the CRT by 16% compared to the conventional method using a polishing treatment and ESR-film. This study provided a method for improving the light output and CRT of a pixelated scintillation crystal-based brain TOF PET detector. The proposed configuration might be an attractive detector design for TOF brain PET requiring fast timing performance with high cost-effectiveness.

About the Influence of the Molecular Structure of selected classes of small molecules on their thermal behavior

  • Richter, Andreas M.;Lischewski, Volker;Felicetti, M.
    • 한국정보디스플레이학회:학술대회논문집
    • /
    • 2004.08a
    • /
    • pp.812-815
    • /
    • 2004
  • The molecular structure influences the thermal behavior of HTM. For OLED the glass transition temperature and evaporation temperature are critical. We report how changes in structure cause changes on both parameters. The results may be of interest for chemists when they design new molecule structures for OLED.

  • PDF

The production and application of therapeutic 67Cu radioisotope in nuclear medicine

  • Kim, Gye-Hong;Lee, Kyo Chul;Park, Ji-Ae;An, Gwang-Il;Lim, Sang Mo;Kim, Jung Young;Kim, Byung Il
    • Journal of Radiopharmaceuticals and Molecular Probes
    • /
    • v.1 no.1
    • /
    • pp.23-30
    • /
    • 2015
  • Radioisotopes emitting low-range highly ionizing radiation such as ${\beta}$-particles are of increasing significance in internal radiotherapy. Among the ${\beta}$-particle emitting radioisotopes, $^{67}Cu$ is an attractive radioisotope for various nuclear medicine applications due to its medium energy ${\beta}$-particle, gamma emissions, and 61.83-hour half-life, which can also be used with $^{64}Cu$ for PET imaging. The production and application of the ${\beta}$-emitting radioisotope $^{67}Cu$ for therapeutic radiopharmaceutical are outlined, and different production routes are discussed. A survey of copper chelators used for antibody labeling is provided. It has been produced via proton, alpha, neutron, and gamma irradiations followed by solvent extraction, ion exchange, electrodeposition. Clinical studies using $^{67}Cu$-labelled antibodies in lymphoma, colon carcinoma and bladder cancer patients are reviewed. Widespread use of this isotope for clinical studies and preliminary treatments has been limited by unreliable supplies, cost, and difficulty in obtaining therapeutic quantities.

Research status for long term half-life PET radioisotopes in KIRAMS

  • Kim, Jung Young;Park, Hyun;Chun, Kwon Soo;An, Gwang Il
    • Journal of Radiopharmaceuticals and Molecular Probes
    • /
    • v.1 no.1
    • /
    • pp.1-8
    • /
    • 2015
  • It is essential use of long term half life radioisotopes for positron emission tomography (PET) imaging study of biopharmaceuticals because most of biopharmaceuticals have long biological half-life. Some representative isotopes are $^{124}I$, $^{64}Cu$, $^{89}Zr$ and so on. These PET radioisotopes and their radiopharmaceuticals have recently received growing interest because of long half life and good imaging properties. Furthermore, $^{64}Cu$ and $^{89}Zr$ can be used in a number of radiopharmaceuticals due to its ease of conjugation to peptides and antibodies using the proper chelator. In recent years, since $^{124}I$ was first developed in 2005, we have been studied to develop an efficient method and procedure for producing these radioisotopes, and we have made considerable progress in production of long term half life radioisotopes. This review introduces the general production system, purification procedure, and several advances on targeting method for $^{124}I$ and $^{64}Cu$ in KIRAMS.

Development of Drugs and Technology for Radiation Theragnosis

  • Jeong, Hwan-Jeong;Lee, Byung Chul;Ahn, Byeong-Cheol;Kang, Keon Wook
    • Nuclear Engineering and Technology
    • /
    • v.48 no.3
    • /
    • pp.597-607
    • /
    • 2016
  • Personalized medicine is tailored medical treatment that targets the individual characteristics of each patient. Theragnosis, combining diagnosis and therapy, plays an important role in selecting appropriate patients. Noninvasive in vivo imaging can trace small molecules, antibodies, peptides, nanoparticles, and cells in the body. Recently, imaging methods have been able to reveal molecular events in cells and tissues. Molecular imaging is useful not only for clinical studies but also for developing new drugs and new treatment modalities. Preclinical and early clinical molecular imaging shows biodistribution, pharmacokinetics, mechanisms of action, and efficacy. When therapeutic materials are labeled using radioisotopes, nuclear imaging with positron emission tomography or gamma camera can be used to treat diseases and monitor therapy simultaneously. Such nuclear medicine technology is defined as radiation theragnosis. We review the current development of drugs and technology for radiation theragnosis using peptides, albumin, nanoparticles, and cells.